Kiromic BioPharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KRBP research report →
Companywww.kiromic.com
Kiromic BioPharma, Inc. , an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1.
- CEO
- Pietro Bersani CPA,
- IPO
- 2020
- Employees
- 44
- HQ
- Houston, TX, US
Price Chart
Valuation
- Market Cap
- $214.93K
- P/E
- -0.08
- P/S
- 0.00
- P/B
- -0.17
- EV/EBITDA
- -0.57
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 247.82%
- ROIC
- -1200.10%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,898,000 · -26.32%
- EPS
- $-1.03 · 95.19%
- Op Income
- $-23,774,000
- FCF YoY
- 7.50%
Performance & Tape
- 52W High
- $3.31
- 52W Low
- $0.05
- 50D MA
- $0.97
- 200D MA
- $1.25
- Beta
- 1.66
- Avg Volume
- 7.89K
Get TickerSpark's AI analysis on KRBP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 26, 24 | BERSANI PIETRO | buy | 988 |
| Aug 23, 24 | BERSANI PIETRO | buy | 2,500 |
| Aug 20, 24 | Hungerford Brian | buy | 3,742 |
| Aug 19, 24 | Hungerford Brian | buy | 258 |
| Aug 13, 24 | Hungerford Brian | buy | 2,000 |
| Jun 12, 24 | Misajon Pamela | buy | 410 |
| Jun 12, 24 | Misajon Pamela | buy | 1,200 |
| Jun 13, 24 | Hungerford Brian | buy | 1,000 |
| Jun 11, 24 | NAGEL MICHAEL | buy | 1,000 |
| Jun 10, 24 | Misajon Pamela | buy | 1,701 |
Our KRBP Coverage
We haven't published any research on KRBP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KRBP Report →